Scinai Immunotherapeutics
SCNI
4 hedge funds and large institutions have $14.9K invested in Scinai Immunotherapeutics in 2026 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 3 closing their positions.
1.8% less ownership
Funds ownership: 2.57% → 0.78% (-1.8%)
43% less funds holding
Funds holding: 7 → 4 (-3)
75% less capital invested
Capital invested by funds: $58.4K → $14.9K (-$43.5K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$24.6K |
| 2 |
VF
Virtu Financial
New York
|
-$11K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$2.62K |
| 4 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
-$712 |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$668 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
XT
1
XTX Topco
George Town,
Cayman Islands
| $13.3K | -$2.62K | -3,253 | -12% |
|
2
RhumbLine Advisers
Boston,
Massachusetts
| $1.04K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $524 | -$668 | -829 | -47% |
|
4
Morgan Stanley
New York
| $33 | – | – | – |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$24.6K | -34,562 | Closed |
|
|
VF
6
Virtu Financial
New York
| – | -$11K | -15,409 | Closed |
|
|
7
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$712 | -1,000 | Closed |
|
SCNI Hedge Fund Activity: Q1 2026 in Review
4 of the 8,127 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q1 2026, worth a combined $14.9K — down 75% from $58.4K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SCNI and 0 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 0 added.
The largest seller was Citadel Advisors, exiting entirely with an estimated $24.6K sold.
- 4 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q1 2026, down from 7 in Q4 2025.
- Funds reported $14.9K of Scinai Immunotherapeutics stock for Q1 2026, down 75% quarter-over-quarter.
- 0 funds opened new Scinai Immunotherapeutics positions in Q1 2026 and 3 closed out, a net change of -3 holders.
- The largest Scinai Immunotherapeutics seller in Q1 2026 was Citadel Advisors, an estimated $24.6K sold.
Based on aggregated 13F filings for Q1 2026.